Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026)
Scynexis' (SCYX) quarterly Total Non-Current Liabilities came in at $17.4 million in Q1 2026, up 41.81% YoY from $12.3 million in Q1 2025, and up 133.78% on a QoQ basis from $7.5 million in Q4 2025.
Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Total Non-Current Liabilities data on file, last reported at $17.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 41.81% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 41.81% YoY) and the FY2025 annual result came in at $7.5 million, down 72.97% from the prior year.
- Total Non-Current Liabilities rose to $17.4 million in Q1 2026, from $7.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $85.1 million in Q2 2022 to a low of $7.5 million in Q4 2025.
- A 5-year average of $36.5 million and a median of $31.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities plunged 72.97% — and 2026, when it jumped 41.81%.
- Tracing SCYX's Total Non-Current Liabilities over 5 years: stood at $66.0 million in 2022, then sank by 48.82% to $33.8 million in 2023, then dropped by 18.37% to $27.6 million in 2024, then sank by 72.97% to $7.5 million in 2025, then soared by 133.78% to $17.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $17.4 million (Q1 2026), $7.5 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | 7.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.24 Mn |
| Mar 31, 2026 | 17.42 Mn |
| Dec 31, 2025 | 7.45 Mn |
| Sep 30, 2025 | 11.10 Mn |
| Jun 30, 2025 | 13.33 Mn |
| Mar 31, 2025 | 12.28 Mn |
| Dec 31, 2024 | 27.57 Mn |
| Sep 30, 2024 | 29.30 Mn |
| Jun 30, 2024 | 29.40 Mn |
| Mar 31, 2024 | 31.95 Mn |
| Dec 31, 2023 | 33.77 Mn |
| Sep 30, 2023 | 31.96 Mn |
| Jun 30, 2023 | 31.69 Mn |
| Mar 31, 2023 | 59.89 Mn |
| Dec 31, 2022 | 65.98 Mn |
| Sep 30, 2022 | 67.35 Mn |
| Jun 30, 2022 | 85.07 Mn |
| Mar 31, 2022 | 64.71 Mn |
| Dec 31, 2021 | 75.23 Mn |
| Sep 30, 2021 | 70.17 Mn |